These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11638)

  • 21. Conformational studies on sequential polypeptides. Part V. Synthesis and characterization of (Pro-Leu-Gly)10, (Pro-LeuqGly)n and (Leu-Pro-Gly)n.
    Scatturin A; Tamburro AM; Vidali G; Bordignon E
    Int J Pept Protein Res; 1975; 7(3):221-8. PubMed ID: 1158560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of nipradilol, a beta-adrenergic blocker with vasodilating activity, on oxotremorine-induced tremor in mice.
    Iwata S; Nomoto M; Fukuda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Oct; 16(5):171-4. PubMed ID: 8962435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vibrational analysis of peptides, polypeptides, and proteins. XVII. Normal modes of crystalline Pro-Leu-Gly-NH2, a type II beta-turn.
    Naik VM; Krimm S
    Int J Pept Protein Res; 1984 Jan; 23(1):1-24. PubMed ID: 6142020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacoethological analysis of the effects of thyroliberin and melanostatin in a model of anxious-defensive behavior in mice].
    Poshivalov VP; Iurkevich AV; Tsakhaev GA
    Biull Eksp Biol Med; 1987 Jun; 103(6):681-3. PubMed ID: 2885047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of peripheral catecholamines in oxotremorine tremor in the rat and its antagonism by beta adrenoceptor blocking agents.
    Weinstock M; Zavadil AP; Rosin AJ; Chiueh CC; Kopin IJ
    J Pharmacol Exp Ther; 1978 Jul; 206(1):91-6. PubMed ID: 26800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Central action of melanostatin and the opiate system of the brain].
    Chepurnova NE; Klusha VE; Borzenkov VM; Lapishin DN; Khatskelevich AIa
    Fiziol Zh SSSR Im I M Sechenova; 1985 Aug; 71(8):937-44. PubMed ID: 2865175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I.
    Kastin AJ; Schally AV; Kostrzewa RM
    Fed Proc; 1980 Sep; 39(11):2931-6. PubMed ID: 6105977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxotremorine-induced cholinergic syndrome: modifications by levodopa and/or oral cytidine diphosphocholine.
    Saligaut C; Daoust M; Chadelaud M; Moore N; Chretien P; Boismare F
    Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):5-8. PubMed ID: 3990445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of analogues of Pro-Leu-Gly-NH2 modified at the leucyl residue.
    Johnson RL; Bontems RJ; Yang KE; Mishra RK
    J Med Chem; 1990 Jun; 33(6):1828-32. PubMed ID: 1971310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and conformational study of two L-prolyl-L-leucyl-glycinamide analogues with a reduced peptide bond.
    Vander Elst P; Elseviers M; De Cock E; Van Marsenille M; Tourwé D; Van Binst G
    Int J Pept Protein Res; 1986 Jun; 27(6):633-42. PubMed ID: 2875969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The central and peripheral effectiveness of two oxotremorine-antagonists determined using oxotremorine-induced tremor and salivation.
    Eicholzer A; Ogren SO
    J Pharm Pharmacol; 1977 Oct; 29(10):609-11. PubMed ID: 21240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Power spectral analysis of tremor induced by TRH and oxotremorine in mice].
    Koja T; Nomoto M; Shimizu T; Izumi K; Fukuda T
    Nihon Yakurigaku Zasshi; 1986 Aug; 88(2):159-65. PubMed ID: 3095204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of L-5HTP on tremorine- or oxotremorine-induced tremor in mice and rats.
    Omori K; Kojima T
    Jpn J Pharmacol; 1973 Dec; 23(6):901-3. PubMed ID: 4274100
    [No Abstract]   [Full Text] [Related]  

  • 35. A selective potentiation by naloxone of L-dopa but not atropine suppression of oxotremorine-induced tremor in mice.
    Quock RM; Lucas TS
    J Pharm Pharmacol; 1985 Sep; 37(9):673-4. PubMed ID: 2867196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Device for quantitating tremor activity in mice: antitremor activity of atropine versus soman- and oxotremorine-induced tremors.
    Clement JG; Dyck WR
    J Pharmacol Methods; 1989 Aug; 22(1):25-36. PubMed ID: 2770314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Some observations on the pharmacological activity of MIF (Pro-Leu-Gly-NH2).
    Turnbull MJ; Wheeler H
    J Pharm Pharmacol; 1980 Nov; 32(11):803-4. PubMed ID: 6110739
    [No Abstract]   [Full Text] [Related]  

  • 38. Stereoselectivity of some oxotremorine antagonists containing two chiral centres.
    Ringdahl B; Resul B; Dahlbom R
    J Pharm Pharmacol; 1979 Dec; 31(12):837-9. PubMed ID: 43369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of MIF-1 and three related peptides on reserpine-induced hypothermia in mice.
    Kastin AJ; Honour LC; Coy DH
    Pharmacol Biochem Behav; 1981 Dec; 15(6):983-5. PubMed ID: 6119707
    [No Abstract]   [Full Text] [Related]  

  • 40. Abolition of oxotremorine effects by L-DOPA pretreatment.
    Korczyn AD; Eshel Y
    Neuropharmacology; 1979 Jul; 18(7):601-3. PubMed ID: 573869
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.